Defining rewardable innovation in drug therapy

被引：41

作者：

Aronson, Jeffrey K. ^{[1
]}

Ferner, Robin E. ^{[2
,3
]}

Hughes, Dyfrig A. ^{[4
]}

机构：

[1] Univ Oxford, Dept Primary Hlth Care, Oxford OX1 2ET, England

[2] City Hosp, W Midlands Ctr Adverse Drug React, Birmingham B18 7QH, W Midlands, England

[3] Univ Birmingham, Sch Clin & Expt Med, Birmingham B15 2TT, W Midlands, England

[4] Bangor Univ, Ctr Hlth Econ & Med Evaluat, Bangor LL57 1UT, Gwynedd, Wales

来源：

NATURE REVIEWS DRUG DISCOVERY | 2012年 / 11卷 / 04期

基金：

英国医学研究理事会;

关键词：

D O I：

10.1038/nrd3715

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Implementing mechanisms for rewarding those who introduce innovative medicinal products requires a definition of 'rewardable innovation'. Here, we propose a definition of innovation with respect to medicinal products, accompanied by a ranking of the importance of different types of innovativeness, with the aim of providing a basis for rewarding such innovation.

引用

页码：253 / 254

页数：2

共 5 条

[1]

Annexe L, 2007, ANN L EV OPT REF PPR

[2] Something New Every Day Defining Innovation and Innovativeness in Drug Therapy [J].

Aronson, Jeffrey K. .

JOURNAL OF AMBULATORY CARE MANAGEMENT, 2008, 31 (01) :65-68

[3] NICE and new: appraising innovation [J].

Ferner, Robin E. ;

Hughes, Dyfrig A. ;

Aronson, Jeffrey K. .

BMJ-BRITISH MEDICAL JOURNAL, 2010, 340

[4] Value-Based Pricing Incentive for Innovation or Zero Net Benefit? [J].

Hughes, Dyfrig A. .

PHARMACOECONOMICS, 2011, 29 (09) :731-735

[5]

Kennedy I., 2009, Appraising the value of innovation and other benefits

← 1 →